208 related articles for article (PubMed ID: 23092556)
21. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor.
Redondo-Müller MA; Stevanovic-Walker M; Barker S; Puddefoot JR; Vinson GP
Endocr Relat Cancer; 2008 Mar; 15(1):277-88. PubMed ID: 18310294
[TBL] [Abstract][Full Text] [Related]
22. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.
Anandanadesan R; Gong Q; Chipitsyna G; Witkiewicz A; Yeo CJ; Arafat HA
J Gastrointest Surg; 2008 Jan; 12(1):57-66. PubMed ID: 18026817
[TBL] [Abstract][Full Text] [Related]
24. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression.
Ohnuma Y; Toda M; Fujita M; Hosono K; Suzuki T; Ogawa Y; Amano H; Kitasato H; Hayakawa K; Majima M
Biomed Pharmacother; 2009 Feb; 63(2):136-45. PubMed ID: 18691848
[TBL] [Abstract][Full Text] [Related]
25. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
Gu JW; Young E; Busby B; Covington J; Johnson JW
Cancer Biol Ther; 2009 Mar; 8(6):514-21. PubMed ID: 19242105
[TBL] [Abstract][Full Text] [Related]
26. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Harada K; Supriatno ; Yoshida H; Sato M
Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
[TBL] [Abstract][Full Text] [Related]
27. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
28. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M
Hum Cell; 2007 Feb; 20(1):1-9. PubMed ID: 17506771
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
[TBL] [Abstract][Full Text] [Related]
30. OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis.
Rebbaa A; Patil G; Yalcin M; Sudha T; Mousa SA
Cancer Lett; 2013 May; 332(1):55-62. PubMed ID: 23348692
[TBL] [Abstract][Full Text] [Related]
31. A precision-guided MWNT mediated reawakening the sunk synergy in RAS for anti-angiogenesis lung cancer therapy.
Su Y; Hu Y; Wang Y; Xu X; Yuan Y; Li Y; Wang Z; Chen K; Zhang F; Ding X; Li M; Zhou J; Liu Y; Wang W
Biomaterials; 2017 Sep; 139():75-90. PubMed ID: 28595131
[TBL] [Abstract][Full Text] [Related]
32. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma.
Otake AH; Mattar AL; Freitas HC; Machado CM; Nonogaki S; Fujihara CK; Zatz R; Chammas R
Cancer Chemother Pharmacol; 2010 May; 66(1):79-87. PubMed ID: 19771429
[TBL] [Abstract][Full Text] [Related]
35. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo.
Bergman Jungeström M; Thompson LU; Dabrosin C
Clin Cancer Res; 2007 Feb; 13(3):1061-7. PubMed ID: 17289903
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin II promotes the progression of human gastric cancer.
Huang MM; Guo AB; Sun JF; Chen XL; Yin ZY
Mol Med Rep; 2014 Mar; 9(3):1056-60. PubMed ID: 24424956
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the therapeutic efficacy of a VEGFR2-blocking antibody using sodium-iodide symporter molecular imaging in a tumor xenograft model.
Cheong SJ; Lee CM; Kim EM; Uhm TB; Jeong HJ; Kim DW; Lim ST; Sohn MH
Nucl Med Biol; 2011 Jan; 38(1):93-101. PubMed ID: 21220132
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.
Chintalapati M; Truax R; Stout R; Portier R; Losso JN
J Agric Food Chem; 2009 Jun; 57(12):5201-10. PubMed ID: 19476359
[TBL] [Abstract][Full Text] [Related]
39. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer.
Okazaki M; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Tajima H; Ninomiya I; Fujimura T; Ohta T
Cancer Lett; 2014 Dec; 355(1):46-53. PubMed ID: 25224569
[TBL] [Abstract][Full Text] [Related]
40. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
